OptiPharm Co Ltd recorded two insider trading transactions within the last ninety days, both involving Representative Director Hyun Il Kim. These acquisitions totaled 14.2 million KRW in purchases. The stock price has experienced a 6.3% increase during this period, occurring ahead of any scheduled earnings report updates.